Press release year list 2022 2021 2020 2019 2018 2017 2016
08/10/2022
Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update
08/02/2022
Evaxion Biotech A/S Announces Executive Management Changes 
07/29/2022
Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10
06/30/2022
Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target
06/23/2022
Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer
06/07/2022
Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital
05/11/2022
Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update
05/10/2022
Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02
04/29/2022
Evaxion Biotech to Host Q1 2022 Corporate Update Conference Call & Webcast on May 11
04/06/2022
Evaxion Biotech Hosting Key Opinion Leader Webinar on Metastatic Melanoma and Personalized Cancer Immunotherapies
03/22/2022
Evaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
03/14/2022
Evaxion Biotech Strengthens Management Team with Two Senior Appointments
03/07/2022
Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02
01/26/2022
Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck
01/18/2022
Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma